Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

694
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
694
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

599
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
599
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.8K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Aortic Regurgitation IV: Nursing Management01:17

Aortic Regurgitation IV: Nursing Management

458
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
458
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autonomic modulation in functional tricuspid regurgitation: effects of transcatheter valve repair.

Heart and vessels·2026
Same author

Prognostic impact of iliofemoral access-site calcification volume on outcomes after transcatheter aortic valve implantation.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Change of Left Ventricular Myocardial Contractility in Speckle Tracking Echocardiography After Transjugular Intrahepatic Portosystemic Shunt Predicts Survival.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Impact of initial rhythm, rhythm at hospital admission and cause of arrest on the outcome of extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest.

The American journal of emergency medicine·2025
Same author

Left Atrial Appendage Closure in Patients Refusing Oral Anticoagulation: The LAAC-REFUSAL Study.

Journal of the American Heart Association·2025
Same author

Mortality after transcatheter aortic valve replacement in young multimorbid patients as compared to an age-, gender- and comorbidity-matched background population.

Frontiers in cardiovascular medicine·2025

Related Experiment Video

Updated: May 6, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.5K

Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement.

Jan-Malte Sinning1, Christoph Hammerstingl, Derek Chin

  • 1Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Bonn, Germany.

Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
|October 31, 2013
PubMed
Summary
This summary is machine-generated.

Severe pulmonary hypertension (PH) significantly increases mortality risk after transcatheter aortic valve replacement (TAVR). However, reducing pulmonary artery systolic pressure (PASP) post-TAVR improves patient outcomes.

More Related Videos

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.0K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

748

Related Experiment Videos

Last Updated: May 6, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.5K
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.0K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

748

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pulmonary Hypertension

Background:

  • Transcatheter aortic valve replacement (TAVR) is a key treatment for severe aortic stenosis.
  • Pulmonary hypertension (PH) is common in these patients and linked to poorer outcomes.
  • The impact of PH on TAVR results requires further elucidation.

Purpose of the Study:

  • To investigate the effect of pre-existing pulmonary hypertension (PH) on outcomes following transcatheter aortic valve replacement (TAVR).
  • To assess the prognostic significance of pulmonary artery systolic pressure (PASP) reduction after TAVR.

Main Methods:

  • Echocardiography was used to measure pulmonary artery systolic pressure (PASP) in 353 patients before and 90 days after TAVR.
  • Patients were categorized into three groups based on baseline PASP: absent (<30 mmHg), mild-to-moderate (30-60 mmHg), and severe (>60 mmHg).
  • Two-year mortality rates were analyzed in relation to baseline PH severity and post-TAVR PASP changes.

Main Results:

  • Higher baseline PASP correlated with increased two-year mortality: 13.9% (no PH), 27.3% (mild-to-moderate PH), and 48.4% (severe PH).
  • In patients with severe PH, PASP significantly decreased from 65.6±7.6 mmHg to 49.5±14.0 mmHg at 90 days post-TAVR.
  • Persistent severe PH post-TAVR was associated with a significantly worse prognosis (50.0% mortality) compared to those with reduced PASP (<60 mmHg, 18.6% mortality).

Conclusions:

  • Severe pulmonary hypertension is a strong predictor of adverse outcomes after TAVR.
  • A reduction in pulmonary artery systolic pressure following TAVR is linked to a more favorable prognosis.